Communiqués Medexus Pharmaceuticals Inc.

Actions

MDP

CA58410Q2036

Produits pharmaceutiques

Marché Fermé - Toronto S.E. 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
5,080 ^CAD	+1,40%		+0,40%	+74,57%

11/08	Transcript : Medexus Pharmaceuticals Inc., Q1 2027 Earnings Call, Aug 11, 2026
11/08	Medexus Pharmaceuticals : hausse annuelle du bénéfice net et du chiffre d'affaires au premier trimestre fiscal	MT

Communiqués

10/08	Medexus Pharmaceuticals : Management Discussion & Analysis Q1 2027	PU
10/08	Medexus Pharmaceuticals : Financial Statements Q1 2027	PU
10/08	Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date	NE
26/06	Medexus Pharmaceuticals : Management Discussion & Analysis FY 2026	PU
26/06	Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection	NE
16/06	Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call	NE
09/06	Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada	NE
15/04	Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation	NE
18/03	Medexus Pharmaceuticals : Investor Presentation (2026.2.26 Presentation)	PU
11/02	Medexus Pharmaceuticals : Management Discussion & Analysis Q3 2026	PU
11/02	Medexus Pharmaceuticals : Financial Statements Q3 2026	PU
11/02	Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection	NE
03/02	Medexus Schedules Third Fiscal Quarter 2026 Conference Call	NE
12/12	Medexus Pharmaceuticals : Investor Presentation (2025.12.1 Presentation)	PU
20/11	Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares	NE
17/11	Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares	NE
13/11	Medexus Pharmaceuticals : Management Discussion & Analysis Q2 2026	PU
13/11	Medexus Pharmaceuticals : Financial Statements Q2 2026	PU
13/11	Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection	NE
04/11	Medexus Schedules Second Fiscal Quarter 2026 Conference Call	NE
25/09/25	Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors	NE
21/08/25	Medexus Pharmaceuticals : Investor Presentation (2025.08.18 PresentationQ12026%281%29)	PU
12/08/25	Medexus Pharmaceuticals : Management Discussion & Analysis Q1 2026	PU
12/08/25	Medexus Pharmaceuticals : Financial Statements Q1 2026	PU
12/08/25	Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection	NE